Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pro-urokinase for infarct therapy]

M Spiecker1, J Meyer

  • 1II. Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität Mainz.

Herz
|December 1, 1994
PubMed
Summary

Saruplase, a recombinant prourokinase, demonstrates effective and fibrin-specific thrombolysis with fewer bleeding complications compared to streptokinase. This agent shows comparable efficacy to urokinase and alteplase in clinical studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Classification of morphologic effects of percutaneous transluminal coronary angioplasty assessed by intravascular ultrasound.

The American journal of cardiology·1992
Same author

Relative sensitivity of four noninvasive methods in assessing systolic cardiovascular effects of isoproterenol in healthy volunteers.

Clinical pharmacology and therapeutics·1992
Same author

[Diagnostic goals in aortic dissection. Value of transthoracic and transesophageal echocardiography].

Herz·1992
Same author

Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes.

Biochemical pharmacology·1992
Same author

[Noninvasive quantification and classification of the severity of aortic stenosis using Doppler echocardiography].

Zeitschrift fur Kardiologie·1992
Same author

Gene order and genetic distance of 13 loci spanning murine chromosome 15.

Genomics·1992

Area of Science:

  • Pharmacology
  • Biochemistry
  • Cardiology

Background:

  • Development of novel thrombolytic agents focuses on enhanced efficacy and fibrin specificity over older agents like streptokinase.
  • Prourokinase, specifically single-chain urokinase-type plasminogen activator (scu-PA), is a key area of research.
  • Recombinant unglycosylated prourokinase (saruplase) is produced in E. coli and possesses a short half-life.

Purpose of the Study:

  • To evaluate the efficacy and safety of saruplase as a thrombolytic agent.
  • To compare saruplase with established thrombolytics such as streptokinase, urokinase, and alteplase.
  • To determine optimal dosing regimens for saruplase in thrombolytic therapy.

Main Methods:

  • Clinical trials including the PASS-study (n=1,698) assessed saruplase efficacy and safety with a 20/60 mg regimen.
  • Randomized multicenter studies compared saruplase against streptokinase (PRIM1-study), urokinase (SUTA-MI-study), and alteplase (SESAM-study).
  • Patency rates, bleeding complications, and hospital mortality were key outcome measures.

Main Results:

  • Saruplase demonstrated significantly higher early patency than streptokinase in the PRIM1-study.
  • Bleeding complications were less frequent with saruplase compared to streptokinase.
  • Patency rates and mortality were similar between saruplase and urokinase/alteplase, with a trend towards earlier patency with saruplase versus alteplase.

Conclusions:

  • Saruplase is an effective and safe thrombolytic agent, particularly noted for its fibrin specificity and reduced bleeding risk.
  • Its efficacy is comparable to urokinase and alteplase, with potential advantages in early reperfusion.
  • The standard 20/60 mg dosage regimen is confirmed as effective.

Related Experiment Videos